ArticleJournal of clinical immunology2016
"How I manage" IgG4-Related Disease.
Article in Journal of clinical immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 50 citations in OpenAlex.
- Article
- New Developments in the Treatment of IgG4-Related Disease: A Comprehensive Clinical Approach.Journal of clinical medicine · 2025Review
- Update on Autoimmune Pancreatitis and IgG4-Related Disease.United European gastroenterology journal · 2025Review
- IgG4-related disease-rare but you should not forget it.Advances in rheumatology (London, England) · 2024Review
- Serum immunoglobulin G4 has limited diagnostic value in immunoglobulin G4-related chronic rhinosinusitis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022Article
- A 61-Year-Old Woman Presenting with Low Back Pain Diagnosed with IgG4-Related Disease Affecting the Thoracoabdominal Aorta and Retroperitoneum.The American journal of case reports · 2022Article
- Proteomic characteristics of saliva in patients with different subgroups of IgG4-RD.Frontiers in immunology · 2022Article
- Mer tyrosine kinase as a possible link between resolution of inflammation and tissue fibrosis in IgG4-related disease.Rheumatology (Oxford, England) · 2021Article
- Unusual presentation of immunoglobulin G4-related disease: A case report.Archives of rheumatology · 2021Article
- IgG4-Related Disease of the Oral Cavity. Case Series from a Large Single-Center Cohort of Italian Patients.International journal of environmental research and public health · 2020Article
- Past, Present, and Future of The Journal of Clinical Immunology, the International Journal of Inborn Errors of Immunity.Journal of clinical immunology · 2020Article
- B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma.Oncoimmunology · 2020Article
- Immunoglobulin G4-related kidney diseases: An updated review.World journal of nephrology · 2018Review
- Immunoglobulin G4-related kidney disease: Pathogenesis, diagnosis, and treatment.Chronic diseases and translational medicine · 2017Review
- Neurological Manifestations of IgG4-Related Disease.Current treatment options in neurology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgG4-related disease (IgG4-RD) is an immune-mediated disease driven by interactions on several levels between cells of the B and T lineages. A key driver of IgG4-RD is believed to be a novel CD4+ cytotoxic T lymphocyte that bears SLAM-F7 on its surface. This cell is presumed to be sustained by continuous antigen presentation by cells of the B cell lineage, particularly plasmablasts. Because IgG4-RD has been recognized for fewer than 15 years as a unified diagnostic entity, no controlled clinical trials or few prospective studies of any sort have been performed. Although progress in understanding disease pathophysiology will likely lead in due course to disease-specific therapies-undoubtedly with implications for other immune-mediated diseases-at this juncture, the management of IgG4-RD remains more an art than a science, driven largely by the published clinical experience of only a few centers of expertise. We identify here six common management dilemmas in IgG4-RD and describe our typical approach to the management of each one.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.